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Abstract. Chagas disease, caused by Trypanosoma cruzi, is transmitted by insect vectors, and through transfusions,
transplants, insect feces in food, andmother to child during gestation. An estimated 30%of infected personswill develop
lifelong, potentially fatal cardiac or digestive complications. Treatment of infantswith benznidazole is highly efficacious in
eliminating infection. This work evaluates the costs of maternal screening and infant testing and treatment for Chagas
disease in theUnited States, including the cost of commercially available benznidazole.We compare costs of testing and
treatment for mothers and infants with the lifetime societal costs without testing and consequent morbidity andmortality
due to lack of treatment or late treatment. We constructed a decision-analytic model, using one tree that shows the
combined costs for every possible mother–child pairing. Savings per birth in a targeted screening program are $1,314,
and with universal screening, $105 per birth. At current screening costs, universal screening results in $420 million in
lifetime savings per birth-year cohort. We found that a congenital Chagas screening program in the United States is cost
saving for all rates of congenital transmission greater than 0.001% and all levels of maternal prevalence greater than
0.06% compared with no screening program.
Chagas disease, caused by the protozoan parasite Trypano-
soma cruzi, can cause serious, even fatal, cardiac and gastroin-
testinal damage in30%ofpersons infected.Maternal transmission
is becoming an increasingly important share of new infections as
the success of other control measures continues. Benznidazole is
highly effective in treating infants and effective in treating adoles-
cents and young adults. Previously, we demonstrated that a uni-
versalprogramofscreeningandtreating infantsandmotherswould
be cost saving. Benznidazole is now approved by the Food and
Drug Administration (FDA) and is commercially available. We
demonstrate that a universal screening and treatment program is
still cost saving in theUnitedStates, evenwith commercially priced
benznidazole.
In August 2017, the US FDA approved benznidazole, one of
two drugs used to treat Chagas disease, for treatment of
children ages 2–12 years and by physician discretion outside
that age range.1Benznidazolebecamecommercially available
onMay 14, 2018.2 In the June 2018 issue (Vol. 98, No. 6) of this
journal (available online April 30, 2018),3 we published an
economic decision-analytic model evaluating the societal
cost of universal screening of pregnant women for Chagas
disease in the United States. This report incorporates the
commercial cost of treatment with benznidazole into our
model of the economic costs and benefits of maternal
screening and treatment for mother–child pairs.
Chagas disease is caused by T. cruzi transmitted by tri-
atomine insects found in Central and South America, Mexico,
and the southern United States.4 An estimated 5.7 million
people in Latin America are infected with T. cruzi, with an
additional 400,000 Latin Americans abroad, primarily in the
United States (about 300,000), Spain, and Japan.5–7 Chagas
disease is also spread by blood transfusions, organ trans-
plants, consumption of insect feces in food, and congenital
transmission.Becauseof success in vector control in endemic
areas and blood screening, congenital transmission accounts
for an increasing share (1/4) of new cases, with approximately
9,000 congenital infections per year in Latin America and
several hundred in the United States and Europe.4,5,8 An es-
timated 30% of infected persons will develop lifelong, po-
tentially fatal cardiac or digestive complications.9,10
Efficacy of benznidazole treatment for infants younger than
1year is 90–100%, and for adults, efficacy ranges from 40% to
70% depending on age and length of time since infection.8,11
Moreover, the risk of congenital transmission is considerably
lower for women treated before pregnancy.12,13 For infected
persons with chronic conditions, treatment has not been found
to remediateexistingcardiacordigestive tractdamage.14A2018
retrospective study, however, found substantial benefits for
persons with chronic Chagas disease who were treated, pri-
marily before the age of 40 years. Comparedwith persons never
treatedwithbenznidazole, the treatmentgrouphadanodds ratio
of 0.21 for mortality within 2 years, of 0.23 for electrocardiogram
(ECG) abnormalities, and of 0.27 for T. cruziDNA on polymerase
chain reaction (PCR).15
The CDC provided benznidazole treatment at no cost for
369 patients from 2011 to 2018 in 41 states and the District of
Columbia.2 Patient enrollment in the CDC program ended in
May 2018 when Exeltis USA, Inc. (Florham Park, NJ) began
commercial supply of benznidazole. Exeltis is a subsidiary of
Insud Pharma, which runs a nonprofit foundation, Mundo
Sano. BetweenMay 2018 and January 2019, 85 patientswith
suspected T. cruzi infection were treated in 19 states
(Exeltis).
To date, there is no maternal screening policy for Chagas
disease in the United States. Food and Drug Administration
approval of benznidazole for treatment of infants is pending
(Exeltis). Early diagnosis could prevent severe and even
deadly complications associated with the chronic stage of the
disease in infants and their mothers. Pregnant women are the
best access point for diagnosing and treating entire families
because delivery is the most likely time for contact with the
healthcare system. In 2017, Hispanics had the highest
* Address correspondence to Eileen Stillwaggon, Department of Eco-
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uninsured rate, 16%, and the lowest rate of private insurance
coverage, 53.5%,16,17 and 30% of Hispanic adults reported
having no usual source of health care, the highest for any
group.18 Hispanic women, on the other hand, have the lowest
rate of out-of-hospital births of any group in theUnited States,
0.05%.19
Using a societal perspective, we compare the costs of
maternal screening and infant testing and treatment as
needed (the screening option) with the costs of no screening,
with its consequent morbidity and mortality due to lack of
treatment or late treatment. We constructed a decision-
analytic model for the United States using TreeAge software
(TreeAge Software Inc., Williamstown, MA) to find the lower
cost option. As before, we use one tree that comprises a de-
cision node (screening or no screening), chance nodes
(probabilities of maternal infection, transmission, and various
degrees of injury), and terminal nodes that correspond to each
possible mother–child outcome. Each outcome represents
the expected value of all economic costs based on a series of
conditional probabilities for each branch.3
Table 1 lists some key parameters for the model. Point es-
timates and ranges are derived from the literature indicated
in the source column. Full description of methods and data
sources appears in the original article and its online supp-
lement.3 Although there have been new studies of Chagas
disease since 2018, none presents new data that would
change themodel parameters, except thecost ofbenznidazole.
The point estimate for screening cost is $60 per pregnancy,
but the model also calculates for screening cost as low as $8
per pregnancy through sensitivity analysis. A new point-of-
care diagnostic test was approved by the FDA in December
2016 for which the expected price will be $4.00 ($8 with
confirmatory test).20,21We list a higher cost for infantPCR than
is in effect to maintain the conservative assumptions of the
earlier article. Currently, Chagas disease PCR testing is only
available at theCDCat no charge. Newborns should be tested
at birth and 4–6 weeks of age.22 To ensure that no infection is
missed by PCR testing, infants who were PCR negative at
both intervals should have serologic testing for antibody to
T. cruzi at the age of 9–10 months, after maternal antibody is
no longer present.22 The cost saving from a maternal
screening program could be especially sensitive to two
clinical variables: prevalence among pregnant women and
mother-to-child transmission risk. For both prevalence and
maternal transmission, we set zero as the lower bound
(Table 1).
Cost-to-charge ratios vary in the United States by state, by
provider, and by coverage. Exeltis provides benznidazole at a
variety of prices (charges), depending on whether the patient
has no insurance, inadequate insurance, orMedicare/Medicaid
coverage. A collaboration of Insud Pharma, Drugs for Neglec-
ted Diseases initiative, and Mundo Sano arranged the sub-
sidization of pricing.23 Mundo Sano covers the gap so that no
patient faces exorbitant costs. For benznidazole, the average
Medicare patient full cost is $401, but patient out-of-pocket
costs are $34.24 Because pharmaceutical pricing in the United
States is essentially unrelated to economic cost, we do not use
Exeltis charges, but rather the Wholesale Acquisition Cost
(WAC). For a full 60-day course of treatment for an infant, the
cost is $180, and for the mother, $720.1,24
We found that commercial provision of benznidazolemade
little difference in the cost savings derived from maternal
screening for Chagas disease. The savings per birth in a
targeted screening program, using prevalence of 0.0131
among Hispanic women from endemic areas, is $1,314, only
$10 less than with free benznidazole. We found that a pro-
gram of universal screening would save $105 per birth,
compared with $106 per birth with free benznidazole.3 The
lower bound maternal prevalence of Chagas disease for
screening to be cost saving is 0.06%. The estimated prev-
alence of Chagas in USwomen of childbearing age is 0.16%.
The results are robust to variations in the rate of mother-to-




Parameter Name in tree Point estimate (range) Sources
Prevalence Prevalence 0.0131 (0.0–0.0131) Ref. 5 (ref. 29,30,32)
Mother-to-child transmission rate MTCT 0.05 (0.0–0.05) Ref. 6,33,34 (ref. 28,32,35–37)
Benznidazole, infant Rx_baby $180 Ref. 1,24
Benznidazole, mother Rx_mom $720 Ref. 1,24
Testing cost, infant Dx_baby $400 Ref. 3
Testing cost, mother Dx_mom $60 ($8–$60) Table 2, multiple sources in ref. 3 (ref. 20)
TABLE 2
Results: lifetime societal costs and savings, no screening, and screening
Scenario
$60 screening cost per birth $8 screening cost per birth
Per birth Per birth-year cohort Per birth Per birth-year cohort
Targeted screening, 480,000 births, maternal prevalence of 1.31%
No screening $2,321 $1,114,080,000 $2,321 $1,114,080,000
Screening $1,007 $483,360,000 $955 $453,600,000
Savings $1,314 $630,720,000 $1,366 $660,480,000
Universal screening, 4,000,000 births, maternal prevalence of 0.16%
No screening $279 $1,116,000,000 $279 $1,116,000,000
Screening $174 $696,000,000 $121 $484,000,000
Savings $105 $420,000,000 $158 $632,000,000
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For screeningwith twopoint-of-care tests at $8, the savings
per birth is $1,366 in a targeted screening program and $158
per birth with universal screening. With the $8 screening cost,
the threshold for screening as the cost-saving option is ma-
ternal prevalence of 0.0000757 (0.008%). It is a construct of
the decision-tree method that the per-birth savings differ
substantially between targeted and universal screening. That
is because the per-birth savings are multiplied in each option
by the number of births, and the total savings are enormous
even in a universal program (Table 2).
Both targeted screening and universal screening are cost
saving over a wide range of prevalence and screening costs in
the United States. The only parameter that makes an impor-
tant difference in the amount of savings from the screening
option is maternal prevalence. Varying mother-to-child
transmission from 0.0 to 0.05 has a trivial effect on the esti-
mate of savings. Thus, even if maternal transmission is ex-
tremely low in the United States because of environmental or
biological factors, that makes little difference in the large
savings from screening. Including the cost of a second infant
PCR makes a trivial difference in the result.
Implementation of universal screening with a point-of-care
test would cost $70.6 million, including screening cost,
benznidazole treatment for mothers and babies, and costs of
enhanced care for women with digestive conditions or in-
determinate status who would not have been identified in the
no-screening scenario. The benefit ($632 million, the dis-
counted present value of the savings) is almost nine times the
cost of the screening program for each birth-year cohort
(Table 3).
Targeted screening toward first- and second-generation
Latinas from endemic areas could be less costly, but surveys
of obstetricians indicate a lack of information about Chagas
disease.22,25 Because the Hispanic population is distributed
across the United States,26 incorporating T. cruzi into routine
screening may be more feasible. The US political climate
makes it risky for many Hispanics to seekmedical attention;27
universal screening avoids profiling and is likely to be more
acceptable to vulnerable women. Pregnant women and
newborns are already screened for a wide variety of genetic
conditions and congenitally transmitted diseases, including
syphilis, HIV, and, in some states, toxoplasmosis, rubella,
and cytomegalovirus.28–30 Our model demonstrates that,
even at current testing costs, maternal screening and follow-
up infant testing and treatment as needed are cost saving for
maternal prevalence as low as 0.057% and for mother-to-
child transmission probability as low as 0.001%. With the
new point-of-care test, universal screening is cost saving
for prevalence as low as 0.008% of pregnant women. Life-
time societal costs, including direct medical costs and
productivity loss due to morbidity and premature mortality,
are 8.9 times the cost of implementing a universal maternal
screening program. This analysis supports adding testing for
T. cruzi infection to routine screening in pregnancy or at the
time of delivery.
The analysis could have limited application in other coun-
tries if subsidized pricing of benznidazole was not available.
On theother hand,USpharmaceutical prices are the highest in
the world.31 A second limitation is the high cost attributed to
infant PCR,but amore realistic cost (currently zero)wouldonly
increase the estimated savings.
Screening and preventive programs in general are often
assumed to be very expensive, especially for low-prevalence
conditions. As this study demonstrates, the lifetime costs of
morbidity and mortality for infected mothers and babies far
outweigh the implementation costs. Moreover, positive se-
rology indicates the need to test the mother’s older children,
as well as the newborn, increasing the benefits. After maternal
treatment, subsequent pregnancies would be protected from
transmission.12,13 Given the outstanding benefits in the earlier
study,3 it is not surprising that the benefits remain even with
commercially available benznidazole. Moreover, the drug
provider has guaranteed affordable pricing, and relatively few
mothers and babies need to be treated. Screening cost, even
at present, is low, and it is likely to be much lower in the near
future. Logistically, universal screening is preferable to tar-
geted screening and is still cost saving.
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